Share your videos with the world

http://blog.topdentistsonline.com/type-2-diabetes-2/ Receiving the diagnosis of type 2 diabetes can be stressful. Some feel like it’s a death sentence. Others may be afraid of the health complications of diabetes. Some feel denial, guilt or anger. These different emotions are part of coming to terms with a life changing diagnosis. But the important thing to remember is that you are not alone.

The story: Innocent debutante Madison Archer has hit the headlines for a scandal not of her making. Now, marriage to the unscrupulous Viktor Beck is the only way to save what’s left of her reputation!The contract: Maddie has always featured in Viktor’s plans to take over her father’s company and expand his empire. The intense attraction between them only sweetens the deal he’s offered….The secret: Though love doesn’t beat in Viktor’s heart, he’ll show Maddie just how hot their chemistry can be. But even this corporate shark is in for a shock—his wild socialite is still a virgin! Find out more at http://www.LucyMonroe.com Romance

CPhI Worldwide, part of UBM Live’s Pharmaceutical Portfolio, today celebrates its 25th birthday by releasing the first in a series of ‘made at CPhI’ pharma stories. These will follow 25 pharma industry successes that have directly resulted from meetings at CPhI. The first story charts Global Pharmaceutical Relief from a first meeting at CPhI only two years ago to today and providing hundreds of millions of dollars worth of medicines to the developing world via NGOs- not just another business story, but a great example of the CPhI family helping to proliferate healthcare throughout the globe. To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762554-cphi-worldwide-celebrates-25-years/

Phenogen Sciences, Inc. today announced the availability of BREVAGenplus, an easy-to-use predictive risk test for the millions of women at risk of developing sporadic, or non-hereditary, breast cancer. The test is an enhancement of the company’s first generation product, BREVAGen®. BREVAGenplus assesses both clinical risk factors and genetic markers known to be associated with sporadic, or non-hereditary, breast cancer to determine a woman’s five-year and lifetime risk of developing the disease. The test is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans for Caucasian, Hispanic and African-American women, age 35 years or above, who have not had breast cancer, lobular carcinoma in situ (LCIS) or ductal carcinoma in situ (DCIS), and have one or more risk factors for developing breast cancer. To view the Multimedia News Release, go to http://www.multivu.com/players/English/7337351-phenogen-sciences-introduces-brevagenplus-breast-cancer-risk-assessment-test/